IN8bio Announces FDA Clearance to Initiate a Phase 2 Clinical Trial of INB-400 Gamma-Delta T Cells for Glioblastoma
08 déc. 2022 07h00 HE
|
IN8bio, Inc
Phase 2 clinical trial initiation expected in 2023 Company to host conference call to discuss recent clinical updates, including updated data from the Phase 1 clinical trial of INB-100 being...
IN8bio Reports Third Quarter 2022 Financial Results and Highlights Recent Company Progress
10 nov. 2022 07h30 HE
|
IN8bio, Inc
INB-100 continued to demonstrate durable morphologic complete responses in the Phase 1 clinical trial in patients with leukemia; on track to announce additional data at upcoming ASH annual...
IN8bio to Present Positive Early Data from Ongoing Phase 1 Study of INB-100 at the 64th American Society of Hematology Annual Meeting
03 nov. 2022 09h10 HE
|
IN8bio, Inc
Data support the potential of INB-100 to induce long-term durable responses in patients with high-risk or relapsed acute myeloid leukemia (AML).Clinical activity observed includes continuing robust...
IN8bio to Present at November Investor Conferences
01 nov. 2022 07h30 HE
|
IN8bio, Inc
NEW YORK, Nov. 01, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies that utilize...
IN8bio to Present at Cantor Oncology & HemOnc Conference
27 sept. 2022 07h30 HE
|
IN8bio, Inc
NEW YORK, Sept. 27, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies that utilize...
IN8bio Partners with the Dunbar CAR T-Cell Program at the University of Louisville as the Manufacturing Center for INB-400
15 sept. 2022 07h30 HE
|
IN8bio, Inc
Agreement provides exclusive access to state-of-the-art GMP manufacturing suites to support Phase 2 clinical studiesPotential to expand the agreement to support commercial-scale manufacturing ...
IN8bio to Present at H.C. Wainwright 24th Annual Global Investment Conference
13 sept. 2022 07h30 HE
|
IN8bio, Inc
NEW YORK, Sept. 13, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies that utilize...
IN8bio Appoints Michael R. Bishop, M.D., to Its Scientific Advisory Board
08 sept. 2022 07h30 HE
|
IN8bio, Inc
NEW YORK, Sept. 08, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies that utilize...
IN8bio to Present at September Investor and Scientific Conferences
30 août 2022 16h15 HE
|
IN8bio, Inc
NEW YORK, Aug. 30, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company discovering and developing innovative gamma-delta T cell therapies that utilize...
IN8bio Announces Closing of Exercise Option to Purchase Additional Shares in Public Offering
19 août 2022 09h20 HE
|
IN8bio, Inc
NEW YORK, Aug. 19, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell...